Latest news with #KORUMedicalSystems
Yahoo
01-05-2025
- Business
- Yahoo
Top Penny Stocks To Watch In May 2025
As the U.S. stock market experiences a positive streak, with the Dow Jones and S&P 500 rising for the eighth consecutive day, investors are keenly observing how major tech earnings influence broader economic sentiment. Penny stocks, though often overlooked due to their historical connotations, remain relevant as potential investment opportunities in this dynamic landscape. These stocks typically represent smaller or newer companies and can offer unexpected growth potential when supported by strong financial fundamentals. In this article, we explore several penny stocks that may stand out for their financial robustness and long-term promise. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.39 $354.37M ★★★★☆☆ Tuya (NYSE:TUYA) $2.35 $1.19B ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $0.9894 $17.95M ★★★★☆☆ Kiora Pharmaceuticals (NasdaqCM:KPRX) $3.30 $9.9M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $3.77 $49.07M ★★★★★★ Waterdrop (NYSE:WDH) $1.31 $481.01M ★★★★★☆ TETRA Technologies (NYSE:TTI) $2.85 $367.28M ★★★★☆☆ BAB (OTCPK:BABB) $0.819475 $5.97M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.625 $81.25M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.785 $72.17M ★★★★★☆ Click here to see the full list of 754 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market both in the United States and internationally, with a market cap of $126.38 million. Operations: The company generates revenue of $33.65 million from its Surgical & Medical Equipment segment. Market Cap: $126.38M KORU Medical Systems, with a market cap of US$126.38 million, is navigating the penny stock landscape by focusing on strategic growth and financial stability despite current unprofitability. The company reported a net loss reduction to US$6.07 million for 2024 from US$13.74 million the previous year, signaling improved cost management. Recent developments include an extended credit facility with HSBC Ventures USA and an agreement with a global pharmaceutical firm to develop advanced infusion systems, potentially enhancing future revenue streams. KORU's experienced management and board support its strategic initiatives while maintaining sufficient cash runway for over three years. Dive into the specifics of KORU Medical Systems here with our thorough balance sheet health report. Assess KORU Medical Systems' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Metalpha Technology Holding Limited, along with its subsidiaries, offers wealth management services in Hong Kong and has a market cap of approximately $69.47 million. Operations: The company generates revenue of $31.40 million from trading proprietary digital assets and derivative contracts. Market Cap: $69.47M Metalpha Technology Holding, with a market cap of US$69.47 million, has shown significant progress in the penny stock arena by becoming profitable this year, reporting a net income of US$6.04 million for the half-year ended September 2024. The company's revenue surged to US$19.72 million from US$5.09 million year-over-year, driven by trading proprietary digital assets and derivative contracts. Despite its volatile share price and an inexperienced management team, Metalpha remains debt-free with strong short-term asset coverage over liabilities and a high return on equity at 24.6%. Recent board changes include appointing CFO Pengyuan Fan as director following Ming Ni's resignation. Get an in-depth perspective on Metalpha Technology Holding's performance by reading our balance sheet health report here. Review our historical performance report to gain insights into Metalpha Technology Holding's track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Applied Energetics, Inc. specializes in the development and sale of advanced lasers, optical systems, and guided energy solutions for various sectors including defense and industrial markets, with a market cap of approximately $149.28 million. Operations: The company's revenue is primarily derived from its Aerospace & Defense segment, totaling $2.43 million. Market Cap: $149.28M Applied Energetics, Inc., with a market cap of US$149.28 million, faces challenges typical of penny stocks, including a net loss of US$9.17 million for 2024 and an auditor's going concern doubt. Despite these hurdles, the company is advancing its strategic collaboration with Kord Technologies to develop an advanced pulsed laser system at its Tucson Battle Lab, potentially opening new defense market opportunities. Recent private placements have provided additional capital following insufficient cash runway projections based on free cash flow estimates. Though unprofitable and lacking significant revenue growth, Applied Energetics has improved its shareholder equity over five years. Navigate through the intricacies of Applied Energetics with our comprehensive balance sheet health report here. Gain insights into Applied Energetics' past trends and performance with our report on the company's historical track record. Unlock our comprehensive list of 754 US Penny Stocks by clicking here. Seeking Other Investments? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:KRMD NasdaqCM:MATH and OTCPK:AERG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
Even after rising 14% this past week, KORU Medical Systems (NASDAQ:KRMD) shareholders are still down 75% over the past five years
This week we saw the KORU Medical Systems, Inc. (NASDAQ:KRMD) share price climb by 14%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 75% in that time. So we don't gain too much confidence from the recent recovery. The million dollar question is whether the company can justify a long term recovery. While the last five years has been tough for KORU Medical Systems shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Because KORU Medical Systems made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. In the last half decade, KORU Medical Systems saw its revenue increase by 6.7% per year. That's a fairly respectable growth rate. So the stock price fall of 12% per year seems pretty steep. The market can be a harsh master when your company is losing money and revenue growth disappoints. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). This free interactive report on KORU Medical Systems' balance sheet strength is a great place to start, if you want to investigate the stock further. It's good to see that KORU Medical Systems has rewarded shareholders with a total shareholder return of 22% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. You might want to assess this data-rich visualization of its earnings, revenue and cash flow. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025
MAHWAH, N.J., April 16, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical's website at The archived webcast will be available for six months. About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Sign in to access your portfolio
Yahoo
27-02-2025
- Business
- Yahoo
KORU Medical Systems, Inc. (KRMD): A Bull Case Theory
We came across a bullish thesis on KORU Medical Systems, Inc. (KRMD) on Substack by Shareholdersunite. In this article, we will summarize the bulls' thesis on KRMD. KORU Medical Systems, Inc. (KRMD)'s share was trading at $3.58 as of Feb 26th. KRMD's trailing P/E was 398.47 according to Yahoo Finance. Ideya/ KORU Medical (KRMD) is a leader in subcutaneous drug delivery solutions, providing patient-friendly infusion systems that are transforming the market. After a period of overvaluation, a recent correction has created an attractive entry point, as KORU benefits from strong industry tailwinds, including the shift from intravenous to subcutaneous immunoglobulin (SCIg), greater adoption of prefilled syringes, international expansion, and its growing role in novel therapy development. The company's FREEDOM System, consisting of portable, maintenance-free infusion devices and consumables, has established itself as a preferred solution for treating conditions like primary immunodeficiency diseases (PIDD), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Paroxysmal Nocturnal Hemoglobinuria (PNH), providing superior patient comfort while reducing healthcare costs. KORU's recurring revenue model, driven by its high-margin consumables business, ensures consistent growth. Its multi-channel sales and distribution approach, which includes direct supply agreements with pharmaceutical companies, specialty pharmacies, and home infusion providers, reinforces its market penetration. Additionally, strict quality controls in U.S. and Nicaraguan manufacturing facilities guarantee compliance with regulatory standards. The company is also investing in R&D to develop a next-generation infusion system, further strengthening its market position. The domestic core business remains the backbone of KORU's growth, with revenue increasing 14% in Q2 2024 and 12% in Q3, outpacing the broader SCIg market. This momentum is driven by growing patient adoption, expanded SCIg drug labels such as XEMBIFY, and a rising CIDP market. Prefilled syringe adoption is another significant tailwind, enhancing convenience and compatibility with KORU's devices. Internationally, the company has seen strong growth, with adjusted revenue increases of 20% in Q2 and 24% in Q3, bringing year-to-date international growth to 38%. With operations now spanning 25 countries and 26 global distributors, KORU is well-positioned to capitalize on expanding SCIg adoption in new markets like Japan and Austria. Novel Therapies is an emerging high-growth segment, with revenues surging 276% in Q3 2024 following a 50% increase in Q2. This segment, which includes feasibility studies, clinical trials, and engineering services for pharmaceutical companies developing subcutaneous biologics, represents a significant long-term growth opportunity. As more therapies transition to subcutaneous delivery, KORU's FREEDOM System stands to benefit, reinforcing its leadership in this expanding market. Financially, KORU has delivered strong performance, with total revenue increasing 17% to $8.2M in Q3 2024, led by 12% growth in domestic core sales and 5% in international sales, which normalized to 25% after accounting for Q2 BSI stocking orders. The Novel Therapies segment contributed $600K, driven by robust product sales supporting clinical trials and non-recurring engineering (NRE) services for six pharmaceutical collaborations. Preliminary Q4 results indicate revenue growth of 23% to $8.9M, bringing FY24 growth to 18% at $33.7M. Profitability is improving, with gross profit up 19% and margins expanding 140 basis points to 63.4%, aided by higher NRE margins and price increases. Cash flow is turning positive, with preliminary Q4 figures showing a $9.6M cash balance, reflecting $0.8M positive cash flow for the quarter and a 67% reduction in FY24 cash burn. With zero debt and access to a $10M credit facility, KORU is financially stable. FY24 guidance has been raised to $32.75M-$33.25M, though preliminary results suggest an even stronger $33.9M. Gross margins are projected at 62%-63%, while operating expenses are expected to land at $24.5M-$25M, excluding stock compensation. KORU anticipates achieving cash flow breakeven in Q4 and sustained positive cash flow in 2025. At $3.6 per share, KORU's market cap stands at $170M, with an enterprise value of $160.5M. It is projected that FY25 revenue of $38.4M, equating to a 4.17x EV/S multiple. While a $0.07 EPS loss is expected, the company's improving fundamentals, margin expansion, and accelerating growth in novel therapies suggest further upside. Despite difficult comps in FY25, momentum is expected to strengthen in FY26, reinforcing the long-term investment case. Investors may find the current $3.5-$3.7 range an attractive entry point, as KORU's disciplined financial management and multiple growth drivers position it for sustained success. KORU Medical Systems, Inc. (KRMD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 15 hedge fund portfolios held KRMD at the end of the third quarter which was 6 in the previous quarter. While we acknowledge the risk and potential of KRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than KRMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
19-02-2025
- Business
- Yahoo
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
MAHWAH, N.J., February 19, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical's website at The archived webcast will be available for six months. About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Sign in to access your portfolio
